150 related articles for article (PubMed ID: 37713138)
1. Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study.
Geisler J; Karihtala P; Tuxen M; Valachis A; ; Holm B
Acta Oncol; 2023 Dec; 62(12):1680-1688. PubMed ID: 37713138
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Davie A; Cuyun Carter G; Rider A; Bailey A; Lewis K; Price G; Ostojic H; Ringeisen F; Pivot X
ESMO Open; 2021 Aug; 6(4):100226. PubMed ID: 34371379
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
5. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven P; Fasching PA; Chia S; Jerusalem G; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Zarate JP; Wang Y; Chakravartty A; Wang C; Slamon DJ
Breast Cancer Res; 2023 Aug; 25(1):103. PubMed ID: 37653397
[TBL] [Abstract][Full Text] [Related]
6. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.
Dalal AA; Gauthier G; Gagnon-Sanschagrin P; Burne R; Guérin A; Niravath P; Small T
Adv Ther; 2018 Sep; 35(9):1356-1367. PubMed ID: 30105655
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
8. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an
Awada A; Gligorov J; Jerusalem G; Preusser M; Singer C; Zielinski C
ESMO Open; 2019; 4(6):e000565. PubMed ID: 31798979
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
11. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
12. The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Meegdes M; Geurts SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Teeuwen NJA; de Boer M; Tjan-Heijnen VCG
Int J Cancer; 2022 Jan; 150(1):124-131. PubMed ID: 34460112
[TBL] [Abstract][Full Text] [Related]
13. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
Breast; 2022 Dec; 66():236-244. PubMed ID: 36368161
[TBL] [Abstract][Full Text] [Related]
14. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Hortobagyi GN
Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
[TBL] [Abstract][Full Text] [Related]
20. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
